SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Pharmaceuticals, Inc. Release: RE-LY® Sub-Analysis Suggests Similar Safety and Efficacy With Pradaxa® (Dabigatran Etexilate Mesylate) Versus Warfarin in NVAF Patients With and Without Diabetes